Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis
Claude Leclerc
Ann Williams
Stewart T. Cole
Caroline Demangel
Roland Brosch
Gilles Marchal
Karen E. Griffiths
Laleh Majlessi
Priscille Brodin
Alexander S. Pym
Nature Medicine, 2003
Alexander Pym
Pym Alexander
ORCID: 0000-0002-6260-8180
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
10.1016/S0140-6736(14)62002-X
Effective anti-tuberculosis therapy correlates with plasma small RNA.
10.1183/09031936.00221214
Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
10.1186/2050-6511-15-61
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
10.1056/NEJMoa1407426
Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility.
10.1128/JCM.02438-14
Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
10.1056/NEJMoa1313865
[In Process Citation].
10.1016/S0399-077X(14)70062-9
Selection of RNA aptamers against the M. tuberculosis EsxG protein using surface plasmon resonance-based SELEX.
10.1016/j.bbrc.2014.04.163
Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
10.1016/S1473-3099(14)70733-9
High rates of potentially infectious tuberculosis and multidrug-resistant tuberculosis (MDR-TB) among hospital inpatients in KwaZulu Natal, South Africa indicate risk of nosocomial transmission.
10.1371/journal.pone.0090868
Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
10.1371/journal.pone.0084866
Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study.
10.1016/S2213-2600(13)70231-5
High-throughput sequencing enhanced phage display identifies peptides that bind mycobacteria.
10.1371/journal.pone.0077844
Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial.
10.1016/S0140-6736(13)62073-5
Consensus standards for introductory e-learning courses in human participants research ethics.
10.1136/medethics-2013-101572
EDCTP regional networks of excellence: initial merits for planned clinical trials in Africa.
10.1186/1471-2458-13-258
Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis.
10.5588/ijtld.12.0017
Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide.
10.1073/pnas.1203636109
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
10.1128/AAC.05526-11
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.
10.1128/AAC.06126-11
International spread of MDR TB from Tugela Ferry, South Africa.
10.3201/eid1711.110291
Drug-Resistant tuberculosis, KwaZulu-Natal, South Africa, 2001-2007.
10.3201/eid1710.100952
Systematic genetic nomenclature for type VII secretion systems.
10.1371/journal.ppat.1000507
The diarylquinoline TMC207 for multidrug-resistant tuberculosis.
10.1056/NEJMoa0808427
Are survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation study.
10.1371/journal.pone.0002363
Challenges in estimating the total burden of drug-resistant tuberculosis.
10.1164/rccm.200801-175PP
Safety of nevirapine in pregnancy.
10.1111/j.1468-1293.2007.00433.x
Evaluation of new antituberculosis drugs in mouse models.
10.1128/AAC.01246-06
Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis.
10.1371/journal.ppat.0020061
Genomic deletions classify the Beijing/W strains as a distinct genetic lineage of Mycobacterium tuberculosis.
10.1128/JCM.43.7.3185-3191.2005
Does resistance to pyrazinamide accurately indicate the presence of Mycobacterium bovis?
10.1128/JCM.43.7.3530-3532.2005
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.
10.1016/j.tube.2004.09.009
High-throughput method for detecting genomic-deletion polymorphisms.
10.1128/JCM.42.7.2913-2918.2004
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.
10.1038/nm859
Proteome analysis of the plasma membrane of Mycobacterium tuberculosis.
10.1002/cfg.211
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti.
10.1046/j.1365-2958.2002.03237.x
Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans.
10.1128/IAI.70.9.4955-4960.2002
A new evolutionary scenario for the Mycobacterium tuberculosis complex.
10.1073/pnas.052548299
Inactivation of the Mycobacterium tuberculosis Nramp orthologue (mntH) does not affect virulence in a mouse model of tuberculosis.
10.1111/j.1574-6968.2002.tb11032.x
The evolution of mycobacterial pathogenicity: clues from comparative genomics.
10.1016/S0966-842X(01)02131-X
Regulation of catalase-peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of Mycobacterium tuberculosis.
10.1046/j.1365-2958.2001.02427.x
Tools for the population genomics of the tubercle bacilli.
10.1101/gr.169200
Comparative genomics uncovers large tandem chromosomal duplications in Mycobacterium bovis BCG Pasteur.
10.1002/1097-0061(20000630)17:2<111::AID-YEA17>3.0.CO;2-G
The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.
10.1089/088922299310278
The in vivo effects of combination antiretroviral drug therapy on peripheral blood CD34+ cell colony-forming units from HIV type 1-infected patients.
10.1089/088922299311079
Post DOTS, post genomics: the next century of tuberculosis control.
10.1016/S0140-6736(99)02118-2
Disease progression and survival in HIV-1-infected Africans in London.
10.1097/00002030-199810000-00013
Disease progression and survival following specific AIDS-defining conditions: a retrospective cohort study of 2048 HIV-infected persons in London.
10.1097/00002030-199809000-00006
Pasteurella multocida abcess in an African patient with human immunodeficiency virus infection.
10.1111/j.1469-0691.1997.tb00484.x
Vancouver: optimism, but at a cost.
10.1258/0956462961918257
Reasons for increased incidence of tuberculosis. Audit suggests that undernotification is common.
10.1136/bmj.311.7004.570a
Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.
10.1016/j.ebiom.2016.05.041
Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance.
10.1038/ng.3548
Assessing Local Risk of Rifampicin-Resistant Tuberculosis in KwaZulu-Natal, South Africa Using Lot Quality Assurance Sampling.
10.1371/journal.pone.0153143
Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.
10.1093/jac/dkv470
Assessing the utility of Xpert(®) MTB/RIF as a screening tool for patients admitted to medical wards in South Africa.
10.1038/srep19391
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
10.1183/13993003.00724-2015
Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.
10.1128/aac.01195-15
Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.
10.1371/journal.pmed.1001880
Completeness and Reliability of the Republic of South Africa National Tuberculosis (TB) Surveillance System.
10.1186/s12889-015-2117-3
Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.
10.5588/ijtld.14.0944
Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing.
10.1186/s12879-015-0967-z
Psychological distress and its relationship with non-adherence to TB treatment: a multicentre study.
10.1186/s12879-015-0964-2
Fatal nosocomial MDR TB identified through routine genetic analysis and whole-genome sequencing.
10.3201/eid2106.141903
Biomarkers for Tuberculosis Based on Secreted, Species-Specific, Bacterial Small Molecules.
10.1093/infdis/jiv312
Impact of tuberculosis treatment and antiretroviral therapy on serial RD-1-specific quantitative T-cell readouts (QuantiFERON-TB Gold In-Tube), and relationship to treatment-related outcomes and bacterial burden.
10.1016/j.ijid.2015.05.006
A Novel Reporter Phage To Detect Tuberculosis and Rifampin Resistance in a High-HIV-Burden Population.
10.1128/jcm.03530-14
Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis.
10.1186/s12916-017-0947-9
Whole-Transcriptome and -Genome Analysis of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Identifies Downregulation of ethA as a Mechanism of Ethionamide Resistance.
10.1128/aac.01461-17
A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide.
10.1038/s41467-017-00721-2
Clofazimine protects against Mycobacterium tuberculosis dissemination in the central nervous system following aerosol challenge in a murine model.
10.1016/j.ijantimicag.2017.08.020
Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa.
10.5588/ijtld.16.0843
Intracellular growth of Mycobacterium tuberculosis after macrophage cell death leads to serial killing of host cells.
10.7554/elife.22028
Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance.
10.1038/ng.3767
Dual-Reporter Mycobacteriophages (Φ2DRMs) Reveal Preexisting Mycobacterium tuberculosis Persistent Cells in Human Sputum.
10.1128/mbio.01023-16
Priscille Brodin
Brodin Priscille
ORCID: 0000-0003-0991-7344
Email: priscille.brodin@inserm.fr
How can nanoparticles contribute to antituberculosis therapy?
10.1016/j.drudis.2017.01.011
Host-directed therapies offer novel opportunities for the fight against tuberculosis
10.1016/j.drudis.2017.05.005
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone
10.3390/toxins9070227
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone
10.3390/toxins9070227
10.3390/toxins9070227.
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections
10.2217/nnm-2016-0364
Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
10.1016/j.ijpharm.2017.05.030.
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism
10.1007/s00401-016-1652-z
Host-directed therapies offer novel opportunities for the fight against tuberculosis
10.1016/j.drudis.2017.05.005
10.1016/j.drudis.2017.05.005.
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria
10.1111/mmi.13535
Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis
10.3389/fcimb.2017.00137
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis
10.1111/cmi.12619
Phenotypic assays for Mycobacterium tuberculosis infection
10.1002/cyto.a.23129
10.1002/cyto.a.23129.
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420
10.1126/science.aag1006
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters
10.1039/c5ob02630j
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization
10.1016/j.str.2016.07.009
Mycolactone The amazing analgesic mycobacterial toxin
10.1051/medsci/20163202007
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection
10.1038/srep29297
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1
10.1021/cb5007163
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo
10.1371/journal.ppat.1004650
High content screening in chemical biology: overview and main challenges
10.1051/medsci/20153102016
High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis
10.1128/aac.03705-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system
10.1016/j.vaccine.2015.03.083
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays
10.1007/978-1-4939-2450-9_24
A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening
10.3791/51114
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches
10.1021/jm500422b
Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways
10.1016/j.cell.2014.04.040
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
A novel specific edge effect correction method for RNA interference screenings
10.1093/bioinformatics/btr648
Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis
10.1021/jm3003779
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors
10.1021/jm200825u
The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence
10.1371/journal.pone.0047573
Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis
10.1371/journal.pone.0026675
Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors
10.1021/jm200076a
High-content screening in infectious diseases
10.1016/j.cbpa.2011.05.023
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ
10.1099/mic.0.038133-0
High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling
10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery
10.4155/fmc.10.223
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting
10.1016/j.biomaterials.2009.09.044
Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure
10.1177/1087057108328762
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
10.1126/science.1171583
High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors
10.1371/journal.ppat.1000645
Systematic Genetic Nomenclature for Type VII Secretion Systems
10.1371/journal.ppat.1000507
Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP
10.1371/journal.ppat.0040033
Aquatic insects and transmission of Mycobacterium ulcerans
10.1051/medsci/20072367572
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity
10.1128/jb.00469-07
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis
10.1371/journal.ppat.0030062
Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva
10.1371/journal.pmed.0040064
Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images
10.1109/isbi.2007.356794
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues
10.1016/j.bmc.2006.12.009
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis
10.1128/iai.74.4.2128-2137.2006
Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents
10.1016/j.bmc.2006.03.033
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence
10.1128/iai.74.1.88-98.2006
High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection
10.1128/iai.02086-05
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence
10.1128/jb.00631-06
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis
10.1016/j.tube.2004.09.009
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity
10.1074/jbc.M503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics
10.1099/mic.0.27799-0
Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions
10.1016/j.jmb.2005.05.049
Tuberculosis: from genome to vaccine
10.1586/14760584.4.4.541
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6
10.1128/iai.72.4.2170-2176.2004
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens
10.1086/421468
ESAT-6 proteins: protective antigens and virulence factors?
10.1016/j.tim.2004.09.007
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex
10.1099/mic.0.26662-0
CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family
10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis
10.1038/nm859
A new evolutionary scenario for the Mycobacterium tuberculosis complex
10.1073/pnas.052548299
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant
10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides
10.1021/bi015732y
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti
10.1046/j.1365-2958.2002.03237.x
6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro
10.1081/ncn-100002322
Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase
10.1021/bi000398b
Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides
10.1023/a:1026631910681
Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase
10.1016/s0014-5793(99)01350-2
Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides
10.1080/07328319908044831
Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions
10.1093/nar/27.15.3029
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus
10.1074/jbc.272.25.16010
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids
10.1073/pnas.1707840114
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton
10.15252/embr.201744371
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton
10.15252/embr.201744371
10.15252/embr.201744371.
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
10.1038/s41598-017-05453-3
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis
10.1038/s41598-017-11843-4
10.1038/s41598-017-11843-4.
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays
10.1021/acschembio.7b00091
Host-pathogen systems for early drug discovery against tuberculosis
10.1016/j.mib.2017.11.017
10.1016/j.mib.2017.11.017.
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages
10.1016/j.chom.2017.07.020
10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling
10.1016/j.celrep.2017.08.101
10.1016/j.celrep.2017.08.101.
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids
10.1073/pnas.1707840114
10.1073/pnas.1707840114.
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors
10.1016/j.celrep.2018.03.125
Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis
10.1016/j.bioorg.2018.08.025
Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation
10.3389/fimmu.2018.00086
Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis
10.1128/aac.00359-18
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase
10.1016/j.tube.2018.08.004
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis
10.1038/s41598-017-11843-4
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
Host-pathogen systems for early drug discovery against tuberculosis
10.1016/j.mib.2017.11.017
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages
10.1016/j.chom.2017.07.020
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling
10.1016/j.celrep.2017.08.101
Phenotypic assays for Mycobacterium tuberculosis infection
10.1002/cyto.a.23129
A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening
10.1002/cyto.a.20627
Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections
10.1002/ppsc.201800360
Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation
10.1074/mcp.RA119.001316
Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters
10.3389/fphar.2019.00378
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis
10.1021/acsnano.8b07902
Mitochondrial Dynamics and Activity in Legionella-Infected Cells
10.1007/978-1-4939-9048-1_13
Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria
10.3389/fmicb.2018.02258
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication
10.1128/jvi.02009-18
A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation
10.1039/C9OB00680J
Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
10.3390/toxins11090516
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies.
10.3389/fimmu.2020.569127
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity.
10.1021/acsinfecdis.9b00277
Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds.
10.1371/journal.pone.0227224
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis.
10.1016/j.vaccine.2019.11.085
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection
10.1101/761551
Worms' Antimicrobial Peptides.
10.3390/md17090512
T(oo)bAd.
10.1038/s41589-019-0347-x
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
10.1038/nm.3262
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
10.1021/jm300377g
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease.
10.1186/1753-6561-5-s1-p38
Automated HTS/HCS for antivirals using visual HIV full replication assays.
10.1186/1742-4690-6-s2-p82
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
10.4049/jimmunol.174.6.3570
Cell microbiology interview
10.1111/cmi.13288
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts
10.1099/mgen.0.000505
Nathalie deboosere
deboosere Nathalie
ORCID: 0000-0002-2873-5485
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton.
10.15252/embr.201744371
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling.
10.1016/j.celrep.2017.08.101
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone.
10.3390/toxins9070227
Phenotypic assays for Mycobacterium tuberculosis infection.
10.1002/cyto.a.23129
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.
10.1021/acschembio.7b00091
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection.
10.1038/srep29297
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis.
10.1111/cmi.12619
A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening.
10.3791/51114
Adhesion of human pathogenic enteric viruses and surrogate viruses to inert and vegetal food surfaces.
10.1016/j.fm.2012.04.007
Viral elution and concentration method for detection of influenza A viruses in mud by real-time RT-PCR.
10.1016/j.jviromet.2011.10.013
Comparison of chlorine and peroxyacetic-based disinfectant to inactivate Feline calicivirus, Murine norovirus and Hepatitis A virus on lettuce.
10.1016/j.ijfoodmicro.2011.08.011
Direct detection of highly pathogenic avian influenza A/H5N1 virus from mud specimens.
10.1016/j.jviromet.2011.06.002
Development and validation of a concentration method for the detection of influenza a viruses from large volumes of surface water.
10.1128/aem.02484-10
A predictive microbiology approach for thermal inactivation of Hepatitis A virus in acidified berries.
10.1016/j.fm.2010.05.018
Assessment of the removal and inactivation of influenza viruses H5N1 and H1N1 by drinking water treatment.
10.1016/j.watres.2010.01.013
Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables.
10.1016/j.ijfoodmicro.2005.11.007
Modelling effect of physical and chemical parameters on heat inactivation kinetics of hepatitis A virus in a fruit model system.
10.1016/j.ijfoodmicro.2003.10.015
Host-pathogen systems for early drug discovery against tuberculosis.
10.1016/j.mib.2017.11.017
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids.
10.1073/pnas.1707840114
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis.
10.1038/s41598-017-11843-4
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages.
10.1016/j.chom.2017.07.020
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
10.1038/s41598-017-05453-3
Host-directed therapies offer novel opportunities for the fight against tuberculosis.
10.1016/j.drudis.2017.05.005
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs.
10.1016/j.ijpharm.2017.05.030
Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis.
10.3389/fcimb.2017.00137
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections.
10.2217/nnm-2016-0364
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.
10.1126/science.aag1006
How can nanoparticles contribute to antituberculosis therapy?
10.1016/j.drudis.2017.01.011
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism.
10.1007/s00401-016-1652-z
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria.
10.1111/mmi.13535
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization.
10.1016/j.str.2016.07.009
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro.
10.1007/s00705-016-2771-5
[Mycolactone: the amazing analgesic mycobacterial toxin].
10.1051/medsci/20163202007
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.
10.1039/c5ob02630j
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.
10.1128/jvi.01473-15
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system.
10.1016/j.vaccine.2015.03.083
Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo.
10.1371/journal.ppat.1004650
[High content screening in chemical biology: overview and main challenges].
10.1051/medsci/20153102016
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays.
10.1007/978-1-4939-2450-9_24
2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
10.1021/cb5007163
High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis.
10.1128/aac.03705-14
Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways.
10.1016/j.cell.2014.04.040
Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches.
10.1021/jm500422b
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
10.1038/nm.3262
The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence.
10.1371/journal.pone.0047573
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
10.1021/jm300377g
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors.
10.1021/jm200825u
A novel specific edge effect correction method for RNA interference screenings.
10.1093/bioinformatics/btr648
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis.
10.1371/journal.pone.0026675
High-content screening in infectious diseases.
10.1016/j.cbpa.2011.05.023
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors.
10.1021/jm200076a
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease.
10.1186/1753-6561-5-s1-p38
High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling.
10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery.
10.4155/fmc.10.223
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ.
10.1099/mic.0.038133-0
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors.
10.1371/journal.ppat.1000645
Systematic genetic nomenclature for type VII secretion systems.
10.1371/journal.ppat.1000507
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting.
10.1016/j.biomaterials.2009.09.044
Automated HTS/HCS for antivirals using visual HIV full replication assays.
10.1186/1742-4690-6-s2-p82
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.
10.1126/science.1171583
Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure.
10.1177/1087057108328762
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP.
10.1371/journal.ppat.0040033
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity.
10.1128/jb.00469-07
[Aquatic insects and transmission of Mycobacterium ulcerans].
10.1051/medsci/20072367572
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis.
10.1371/journal.ppat.0030062
Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva.
10.1371/journal.pmed.0040064
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues.
10.1016/j.bmc.2006.12.009
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence.
10.1128/jb.00631-06
High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.
10.1128/iai.02086-05
Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents.
10.1016/j.bmc.2006.03.033
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.
10.1128/iai.74.4.2128-2137.2006
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence.
10.1128/iai.74.1.88-98.2006
Tuberculosis: from genome to vaccine.
10.1586/14760584.4.4.541
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity.
10.1074/jbc.m503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics.
10.1099/mic.0.27799-0
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
10.4049/jimmunol.174.6.3570
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.
10.1016/j.tube.2004.09.009
ESAT-6 proteins: protective antigens and virulence factors?
10.1016/j.tim.2004.09.007
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.
10.1086/421468
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6.
10.1128/iai.72.4.2170-2176.2004
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex.
10.1099/mic.0.26662-0
CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family.
10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.
10.1038/nm859
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti.
10.1046/j.1365-2958.2002.03237.x
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant.
10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides.
10.1021/bi015732y
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection
10.1101/761551
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
Roland Brosch
Brosch Roland
ORCID: 0000-0003-2587-3863
Mycobacterium tuberculosis Meets the Cytosol: The Role of cGAS in Anti-mycobacterial Immunity.
10.1016/j.chom.2015.05.017
Insights on the emergence of Mycobacterium tuberculosis from the analysis of Mycobacterium kansasii
10.1093/gbe/evv035
Mycobacterial Pathogenomics and Evolution.
10.1128/microbiolspec.MGM2-0025-2013
Release of mycobacterial antigens
10.1111/imr.12251
Mycobacterium abscessus phospholipase C expression is induced during coculture within amoebae and enhances M. abscessus virulence in mice
10.1128/IAI.02032-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system
10.1016/j.vaccine.2015.03.083
Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations
10.1038/srep15443
ESX/type VII secretion systems of mycobacteria: Insights into evolution, pathogenicity and protection
10.1016/j.tube.2015.02.019
Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014
10.1016/j.vaccine.2015.03.056
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo
10.1371/journal.ppat.1004650
Bovine tubercle bacilli: evolution associated with loss of transmission capacity in humans | Les bacilles de la tuberculose bovine - Une évolution aux dépens de la transmissibilité chez l'homme
10.1051/medsci/20153102003
Mycobacterium tuberculosis Exploits Asparagine to Assimilate Nitrogen and Resist Acid Stress during Infection
10.1371/journal.ppat.1003928
Mycobacterium tuberculosis evolutionary pathogenesis and its putative impact on drug development
10.2217/fmb.14.70
Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator
10.1073/pnas.1406693111
Bacillus calmette-guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy
10.1016/j.eururo.2014.02.061
A Specific polymorphism in Mycobacterium tuberculosis H37Rv causes differential ESAT-6 expression and identifies whiB6 as a novel ESX-1 component
10.1128/IAI.01824-14
A glimpse into the past and predictions for the future: The molecular evolution of the tuberculosis agent
10.1111/mmi.12720
TBCAP; Tuberculosis annotation project
10.1016/j.tube.2012.11.013
Identification and characterization of the genetic changes responsible for the characteristic smooth-to-rough morphotype alterations of clinically persistent Mycobacterium abscessus
10.1111/mmi.12387
Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis
10.1038/ng.2517
ESX-1-induced apoptosis is involved in cell-to-cell spread of Mycobacterium tuberculosis
10.1111/cmi.12169
Characterization of Mycobacterium orygis
10.3201/eid1903.121005
The ESX-5 Associated eccB5-eccC5 Locus Is Essential for Mycobacterium tuberculosis Viability
10.1371/journal.pone.0052059
Strong immunogenicity and cross-reactivity of Mycobacterium tuberculosis ESX-5 type VII secretion-encoded PE-PPE proteins predicts vaccine potential
10.1016/j.chom.2012.03.003
Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death
10.1371/journal.ppat.1002507
Multidrug-resistant tuberculosis in admitted patients at a tertiary referral hospital of Bangladesh
10.1371/journal.pone.0040545
Molecular epidemiology of tuberculosis in rural Matlab, Bangladesh
10.5588/ijtld.11.0426
ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria
10.1111/j.1462-5822.2012.01799.x
ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells
10.4161/auto.20881
Disruption of the ESX-5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation
10.1111/j.1365-2958.2012.08001.x
Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies
10.3201/eid1804.110888
Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis
10.1002/eji.201141548
p62 and NDP52 proteins target intracytosolic Shigella and Listeria to different autophagy pathways
10.1074/jbc.M111.223610
Overexpression of proinflammatory TLR-2-signalling lipoproteins in hypervirulent mycobacterial variants
10.1111/j.1462-5822.2010.01565.x
ESAT-6 secretion-independent impact of ESX-1 genes espF and espG 1on virulence of Mycobacterium tuberculosis
10.1093/infdis/jiq089
Deciphering the role of IS6110 in a highly transmissible Mycobacterium tuberculosis Beijing strain, GC1237
10.1016/j.tube.2010.12.007
Synthesis, biological activity, and evaluation of the mode of action of novel antitubercular benzofurobenzopyrans substituted on A ring
10.1016/j.ejmech.2010.09.048
High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling
10.1371/journal.ppat.1001100
Entrapment of intracytosolic bacteria by septin cage-like structures
10.1016/j.chom.2010.10.009
Systematic genetic nomenclature for type VII secretion systems
10.1371/journal.ppat.1000507
Pathogenomics of mycobacteria
10.1159/000235772
Pathogenicity in the tubercle bacillus: Molecular and evolutionary determinants
10.1002/bies.200800191
Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus
10.1371/journal.pone.0005660
Myths and misconceptions: The origin and evolution of Mycobacterium tuberculosis
10.1038/nrmicro2165
Mycobacterial PE, PPE and ESX clusters: Novel insights into the secretion of these most unusual protein families
10.1111/j.1365-2958.2009.06784.x
High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors
10.1371/journal.ppat.1000645
ESX/type VII secretion systems and their role in host-pathogen interaction
10.1016/j.mib.2008.11.003
Benzothiazinones Kill Mycobacterium tuberculosis by blocking Arabinan synthesis
10.1126/science.1171583
Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis
10.1101/gr.075069.107
Functional analysis of a clonal deletion in an epidemic strain of Mycobacterium bovis reveals a role in lipid metabolism
10.1099/mic.0.2008/022269-0
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP
10.1371/journal.ppat.0040033
BCG: Molecular history and new perspectives | Le BCG: Histoire moléculaire et nouvelles perspectives
RMR-06-2008-25-00-01761-8425-101019-200806495
Genome plasticity of BCG and impact on vaccine efficacy
10.1073/pnas.0700869104
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity
10.1128/JB.00469-07
Pathogenomics: Insights into Tuberculosis and Related Mycobacterial Diseases
10.1002/352760801X.ch10
Horizontal transfer of a virulence operon to the ancestor of Mycobacterium tuberculosis
10.1093/molbev/msj120
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence
10.1128/IAI.74.1.88-98.2006
Contribution of mycobacterial genomics to the development of innovative strategies against tuberculosis | Apports de la génomique des mycobactéries a la définition de nouvelles stratégies thérapeutiques et vaccinales anti-tuberculeuses
10.1016/S1773-035X(06)80148-6
"A re-evaluation of M. prototuberculosis": Continuing the debate
10.1371/journal.ppat.0020095
Tuberculosis: From genome to vaccine
10.1586/14760584.4.4.541
Structure and mechanism of the alkyl hydroperoxidase AhpC, a key element of the Mycobacterium tuberculosis defense system against Oxidative Stress
10.1074/jbc.M503076200
Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: The contribution of endogenous mycolactone toxin
10.1111/j.1462-5822.2005.00546.x
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity
10.1074/jbc.M503515200
Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans
10.1128/JB.187.5.1668-1676.2005
Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis
10.1371/journal.ppat.0010005
Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans
10.1073/pnas.0305877101
Genotypic Analysis of Mycobacterium tuberculosis in Bangladesh and Prevalence of the Beijing Strain
10.1128/JCM.42.2.674-682.2004
ESAT-6 proteins: Protective antigens and virulence factors?
10.1016/j.tim.2004.09.007
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens
10.1086/421468
Cell Envelope Protein PPE68 Contributes to Mycobacterium tuberculosis RD1 Immunogenicity Independently of A 10-Kilodalton Culture Filtrate Protein and ESAT-6
10.1128/IAI.72.4.2170-2176.2004
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis
10.1038/nm859
Is Mycobacterium africanum subtype II (Uganda I and Uganda II) a genetically well-defined subspecies of the Mycobacterium tuberculosis complex? [3] (multiple letters)
10.1128/JCM.41.3.1345-1348.2003
Royal society of tropical medicine and hygiene meeting at Manson house, London, 18 January 2001: Pathogen genomes and human health. Mycobacterial genomics
10.1016/S0035-9203(02)90222-1
Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis
10.1128/JCM.40.7.2339-2345.2002
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti
10.1046/j.1365-2958.2002.03237.x
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant
10.1128/IAI.70.10.5568-5578.2002
A new evolutionary scenario for the Mycobacterium tuberculosis complex
10.1073/pnas.052548299
The evolution of mycobacterial pathogenicity: Clues from comparative genomics
10.1016/S0966-842X(01)02131-X
Genomics of Mycobacterium bovis
10.1054/tube.2000.0269
Tools for the population genomics of the tubercle bacilli
10.1101/gr.169200
Comparative genomics of the leprosy and tubercle bacilli
10.1016/S0923-2508(00)00117-0
Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays
10.1046/j.1365-2958.1999.01383.x
Analysis of the proteome of Mycobacterium tuberculosis in silico
10.1054/tuld.1999.0220
The high-pathogenicity island of Yersinia pseudotuberculosis can be inserted into any of the three chromosomal asn tRNA genes
10.1046/j.1365-2958.1998.01124.x
Deciphering the biology of mycobacterium tuberculosis from the complete genome sequence
10.1038/31159
Genomic fingerprinting of 80 strains from the WHO multicenter international typing study of Listeria monocytogenes via pulsed-field gel electrophoresis (PFGE)
10.1016/S0168-1605(96)01147-6
Characterization of Listeria strains isolated from soft cheese
10.1016/0168-1605(93)90220-B
Listeriosis outbreak in France in 1992. Microbial data | Epidémie de listériose en France en 1992 aspects microbiologiques
10.1016/S0399-077X(05)81214-4
Use of pulsed field gel electrophoresis to compare large DNA-restriction fragments of Listeria monocytogenes strains belonging to serogroups 1/2 and 3
10.1016/0168-1605(91)90121-5
Subtyping of Listeria monocytogenes serovar 4b by use of low-frequency-cleavage restriction endonucleases and pulsed-field gel electrophoresis
10.1016/0923-2508(91)90080-T
Impact of Mycobacterium tuberculosis RD1-locus on human primary dendritic cell immune functions
10.1038/srep17078
Revisiting the role of phospholipases C in virulence and the lifecycle of Mycobacterium tuberculosis
10.1038/srep16918
Drug-resistant tuberculosis in the European Union: opportunities and challenges for control.
10.1016/j.tube.2010.03.008
The BCG Strain Pool: Diversity Matters.
10.1038/mt.2016.18
Genome-wide mosaicism within Mycobacterium abscessus: evolutionary and epidemiological implications.
10.1186/s12864-016-2448-1
Perspectives on mycobacterial vacuole-to-cytosol translocation: the importance of cytosolic access.
10.1111/cmi.12622
Key experimental evidence of chromosomal DNA transfer among selected tuberculosis-causing mycobacteria
10.1073/pnas.1604921113
Comparative Genomics and Evolution of Mycobacterium bovis BCG
10.1128/9781555817657.ch10
The Mycobacteria: a Postgenomic View
10.1128/9781555815530.ch3
Genomics ofMycobacterium Tuberculosis and Mycobacterium Leprae
10.1002/9781444311433.ch5
Genomics of the Mycobacterium tuberculosis complex and Mycobacterium leprae
10.1002/047001153x.g205204
ESX secretion systems: mycobacterial evolution to counter host immunity
10.1038/nrmicro.2016.131
Resistance to thiacetazone derivatives active against Mycobacterium abscessus involves mutations in the MmpL5 transcriptional repressor MAB_4384
10.1128/aac.02509-16
ESX-1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosis.
10.1111/cmi.12726
Colonization with Helicobacter is concomitant with modified gut microbiota and drastic failure of the immune control of Mycobacterium tuberculosis
10.1038/mi.2016.140
Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection
10.1016/j.celrep.2017.02.057
PknG senses amino acid availability to control metabolism and virulence of Mycobacterium tuberculosis
10.1371/journal.ppat.1006399
Predicting susceptibility to tuberculosis based on gene expression profiling in dendritic cells
10.1038/s41598-017-05878-w
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling
10.1016/j.celrep.2017.08.101
Evolution of virulence in the Mycobacterium tuberculosis complex
10.1016/j.mib.2017.11.021
The Macrophage: A Disputed Fortress in the Battle against Mycobacterium tuberculosis
10.3389/fmicb.2017.02284
Mutations in ppe38 block PE_PGRS secretion and increase virulence of Mycobacterium tuberculosis
10.1038/s41564-017-0090-6
Discovery of the type VII ESX-1 secretion needle?
10.1111/mmi.13579
Identification of genes required forMycobacterium abscessusgrowth in vivo with a prominent role of the ESX-4 locus
10.1073/pnas.1713195115
Mycobacterial ESX-1 secretion system mediates host cell lysis through bacterium contact-dependent gross membrane disruptions
10.1073/pnas.1620133114
Horizontal acquisition of a hypoxia-responsive molybdenum cofactor biosynthesis pathway contributed to Mycobacterium tuberculosis pathoadaptation
10.1371/journal.ppat.1006752
The Biology and Epidemiology of Mycobacterium canettii
10.1007/978-3-319-64371-7_2
Targeting Type VII/ESX Secretion Systems for Development of Novel Antimycobacterial Drugs
10.2174/1381612819666131118170717
Taxonomic Diversity of Pseudomonads Revealed by Computer-interpretation of Ribotyping Data
10.1016/s0723-2020(96)80026-9
Comparative genomics of the mycobacteria
10.1016/s1438-4221(00)80083-1
Single Cell Measurements of Vacuolar Rupture Caused by Intracellular Pathogens
10.3791/50116
Type VII Secretion Systems in Gram-Positive Bacteria
10.1007/82_2015_5015
Genomic characterization of Mycobacterium tuberculosis lineage 7 and a proposed name: ‘Aethiops vetus’
10.1099/mgen.0.000063
Leprosy in red squirrels
10.1126/science.aal0145
CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection
10.1371/journal.ppat.1005770
pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence
10.1038/nmicrobiol.2015.19
A unique PE_PGRS protein inhibiting host cell cytosolic defenses and sustaining full virulence ofMycobacterium marinumin multiple hosts
10.1111/cmi.12606
The PE and PPE Protein Families of Mycobacterium tuberculosis
10.1002/9783527611614.ch7
Influence of ESAT-6 Secretion System 1 (RD1) of Mycobacterium tuberculosis on the Interaction between Mycobacteria and the Host Immune System
10.4049/jimmunol.174.6.3570
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors
10.1016/j.celrep.2018.03.125
ESAT-6–dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivo
10.1172/jci84978
Cutting-edge science and the future of tuberculosis control
10.2471/blt.06.035386
ESAT-6 and the Mycobacterial ESX Secretion Systems
10.1128/9781555815783.ch13
RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection
10.1371/journal.ppat.1007139
Unexpected genomic and phenotypic diversity of Mycobacterium africanum Lineage 5 affects drug resistance, protein secretion and immunogenicity
10.1093/gbe/evy145
New substrates and interactors of the mycobacterial Serine/Threonine protein kinase PknG identified by a tailored interactomic approach
10.1016/j.jprot.2018.09.013
Update on the virulence factors of the obligate pathogen Mycobacterium tuberculosis and related tuberculosis-causing mycobacteria
10.1016/j.meegid.2018.12.013
Shared Pathogenomic Patterns Characterize a New Phylotype, Revealing Transition toward Host-Adaptation Long before Speciation of Mycobacterium tuberculosis
10.1093/gbe/evz162
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis.
10.1021/acsnano.8b07902
Mycobacterial virulence: impact on immunogenicity and vaccine research
10.12688/f1000research.20572.1
TbD1 deletion as a driver of the evolutionary success of modern epidemic Mycobacterium tuberculosis lineages
10.1038/s41467-020-14508-5
Discovery of a novel dehydratase of the fatty acid synthase type II critical for ketomycolic acid biosynthesis and virulence of Mycobacterium tuberculosis
10.1038/s41598-020-58967-8
ESX/Type VII Secretion Systems—An Important Way Out for Mycobacterial Proteins
10.1128/microbiolspec.psib-0029-2019
ESX-4, un système de sécrétion mycobactérien ancestral, essentiel pour la croissance de Mycobacterium abscessus dans les phagocytes environnementaux et humains
10.1051/medsci/2018196
Mycobacterium abscessus virulence traits unraveled by transcriptomic profiling in amoeba and macrophages
10.1371/journal.ppat.1008069
A systematic approach to simultaneously evaluate safety, immunogenicity, and efficacy of novel tuberculosis vaccination strategies
10.1126/sciadv.aaz1767
Live attenuated TB vaccines representing the three modern Mycobacterium tuberculosis lineages reveal that the Euro–American genetic background confers optimal vaccine potential
10.1016/j.ebiom.2020.102761
Mucosal delivery of ESX-1–expressing BCG strains provides superior immunity against tuberculosis in murine type 2 diabetes
10.1073/pnas.2003235117
Le BCG : histoire moléculaire et nouvelles perspectives
10.1016/s0761-8425(08)56032-3
Breaching the phagosome, the case of the tuberculosis agent
10.1111/cmi.13344
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts
10.1099/mgen.0.000505
The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection
10.7554/elife.55692
IL-1R1-Dependent Signals Improve Control of Cytosolic Virulent Mycobacteria In Vivo
10.1128/mSphere.00153-21
ESX-1-Independent Horizontal Gene Transfer by Mycobacterium tuberculosis Complex Strains
10.1128/mBio.00965-21
Evolution of Mycobacterium tuberculosis : New Insights into Pathogenicity and Drug Resistance
10.1128/microbiolspec.tbtb2-0020-2016
Phthiocerol Dimycocerosates From Mycobacterium tuberculosis Increase the Membrane Activity of Bacterial Effectors and Host Receptors
10.3389/fcimb.2020.00420
Parallel in vivo experimental evolution reveals that increased stress resistance was key for the emergence of persistent tuberculosis bacilli
10.1038/s41564-021-00938-4
Caroline Demangel
Demangel Caroline
ORCID: 0000-0001-7848-586X
Recombinant Antibodies against Mycolactone
10.3390/toxins11060346
Shaping mycolactone for therapeutic use against inflammatory disorders
10.1126/SCITRANSLMED.AAB0458
Synthetic Variants of Mycolactone Bind and Activate Wiskott-Aldrich Syndrome Proteins
10.1021/JM5008819
Adhesion of the ulcerative pathogen Mycobacterium ulcerans to DACC-coated dressings
10.12968/JOWC.2014.23.8.417
Understanding Buruli Ulcer (Mycobacterium ulcerans Disease)
10.1128/9781555816803.CH12
Ipomoeassin F Binds Sec61 alpha to Inhibit Protein Translocation
10.1021/JACS.8B13506
Mycolactone subverts immunity by selectively blocking the Sec61 translocon
10.1084/JEM.20160662
Functional Analysis via Standardized Whole-Blood Stimulation Systems Defines the Boundaries of a Healthy Immune Response to Complex Stimuli
10.1016/J.IMMUNI.2014.03.002
Proteomic Analysis of the SH2Domain-containing Leukocyte Protein of 76 kDa (SLP76) Interactome
10.1074/MCP.M112.025908
Pathogenesis of skin ulcers: lessons from the Mycobacterium ulcerans and Leishmania spp. pathogens
10.1007/S00018-014-1561-Z
Buruli ulcer disease: prospects for a vaccine
10.1007/S00430-009-0109-6
Combined Inflammatory and Metabolic Defects Reflected by Reduced Serum Protein Levels in Patients with Buruli Ulcer Disease
10.1371/JOURNAL.PNTD.0002786
Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production
10.1002/1521-4141(200204)32:4<994::AID-IMMU994>3.3.CO;2-Y
Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans
10.1038/NRMICRO2077
Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients - Implications for Diagnosis and Disease Monitoring
10.1371/JOURNAL.PNTD.0001237
Molecular Mimicry between a Monoclonal Antibody and One Subunit of Crotoxin, a Heterodimeric Phospholipase A2 Neurotoxin
10.1515/BC.1999.071
Antigen Discovery: a Postgenomic Approach to Leprosy Diagnosis
10.1128/IAI.74.1.175-182.2006
Zika virus induces massive cytoplasmic vacuolization and paraptosis‐like death in infected cells
10.15252/EMBJ.201695597
Comparison of various methods for monitoring hybridoma cell proliferation
10.1016/0022-1759(90)90379-A
Immunosuppressive Signature of Cutaneous Mycobacterium ulcerans Infection in the Peripheral Blood of Patients with Buruli Ulcer Disease
10.1086/646615
Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer
10.1126/SCITRANSLMED.3003586
Mycobacterial Phenolic Gycolipids Selectively Disable TRIF-Dependent TLR4 Signaling in Macrophages
10.3389/FIMMU.2018.00002
A Diverted Total Synthesis of Mycolactone Analogues: An Insight into Buruli Ulcer Toxins
10.1002/CHEM.201102542
Mycobacterium leprae Phenolglycolipid-1 Expressed by Engineered M. bovis BCG Modulates Early Interaction with Human Phagocytes
10.1371/JOURNAL.PPAT.1001159
Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone
10.1084/JEM.20070234
Sec61 blockade by mycolactone inhibits antigen cross-presentation independently of endosome-to-cytosol export
10.1073/PNAS.1705242114
Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin
10.1111/J.1462-5822.2005.00546.X
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6
10.1128/IAI.72.4.2170-2176.2004
Mycolactone displays anti-inflammatory effects on the nervous system
10.1371/JOURNAL.PNTD.0006058
Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression
10.1073/PNAS.1016496108
A Novel Mycolactone Toxin Obtained by Biosynthetic Engineering
10.1002/CBIC.200700411
Targeting Dendritic Cells with Antigen-Containing Liposomes
10.1158/0008-5472.CAN-04-0138
Proteomics Reveals Scope of Mycolactone-mediated Sec61 Blockade and Distinctive Stress Signature
10.1074/MCP.RA118.000824
Dendritic cells infected with Mycobacterium bovis bacillus Calmette Guerin activate CD8(+) T cells with specificity for a novel mycobacterial epitope
10.1093/INTIMM/13.4.451
Modular total syntheses of mycolactone A/B and its [ 2 H]-isotopologue
10.1039/C7OB01943B
TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection
10.4049/JIMMUNOL.168.9.4620
Factors controlling cell proliferation and antibody production in mouse hybridoma cells: I. Influence of the amino acid supply
10.1002/BIT.260380602
Differential Effects of Prior Exposure to Environmental Mycobacteria on Vaccination with Mycobacterium bovis BCG or a Recombinant BCG Strain Expressing RD1 Antigens
10.1128/IAI.73.4.2190-2196.2005
Phage-displayed and soluble mouse scFv fragments neutralize rabies virus
10.1016/S0166-0934(97)00099-2
Towards an immunodiagnostic test for leprosy
10.1016/J.MICINF.2006.04.002
Interaction of dendritic cells with mycobacteria: Where the action starts
10.1046/J.1440-1711.2000.00935.X
Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation
10.1172/JCI66576
Stimulation of Dendritic Cells via CD40 Enhances Immune Responses to Mycobacterium tuberculosis Infection
10.1128/IAI.69.4.2456-2461.2001
Role of Metabolic Waste Products in the Control of Cell Proliferation and Antibody Production by Mouse Hybridoma Cells
10.1089/HYB.1992.11.311
Inactivation of Rv2525c, a Substrate of the Twin Arginine Translocation (Tat) System of Mycobacterium tuberculosis, Increases -Lactam Susceptibility and Virulence
10.1128/JB.00631-06
Protection against aerosol Mycobacterium tuberculosis infection using Mycobacterium bovis Bacillus Calmette Guerin-infected dendritic cells
10.1002/(SICI)1521-4141(199906)29:06<1972::AID-IMMU1972>3.3.CO;2-T
Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism
10.1099/0022-1317-82-8-1885
Mycolactone Suppresses T Cell Responsiveness by Altering Both Early Signaling and Posttranslational Events
10.4049/JIMMUNOL.0902854
Mycolactone Diffuses from Mycobacterium ulcerans–Infected Tissues and Targets Mononuclear Cells in Peripheral Blood and Lymphoid Organs
10.1371/JOURNAL.PNTD.0000325
Dissection of ESAT-6 System 1 of Mycobacterium tuberculosis and Impact on Immunogenicity and Virulence
10.1128/IAI.74.1.88-98.2006
Tuberculosis: from genome to vaccine
10.1586/14760584.4.4.541
Single chain antibody fragments for the selective targeting of antigens to dendritic cells
10.1016/J.MOLIMM.2004.09.034
Standardized Whole-Blood Transcriptional Profiling Enables the Deconvolution of Complex Induced Immune Responses
10.1016/J.CELREP.2016.08.011
Lipids of Pathogenic Mycobacteria: Contributions to Virulence and Host Immune Suppression
10.1111/J.1865-1682.2009.01072.X
Biologically active human anti-crotoxin scFv isolated from a semi-synthetic phage library
10.1016/S1380-2933(97)00068-7
Combining phage display and molecular modeling to map the epitope of a neutralizing antitoxin antibody
10.1046/J.1432-1327.2000.01244.X
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis
10.1038/NM859
Metabolomic profiles delineate mycolactone signature in Buruli ulcer disease
10.1038/SREP17693
Reproducing the immune response against the Plasmodium vivax merozoite surface protein 1 with mimotopes selected from a phage-displayed peptide library
10.1016/S0161-5890(96)00058-2
Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer
10.1016/J.MICINF.2006.03.009
Lactate dehydrogenase (LDH) activity of the number of dead cells in the medium of cultured eukaryotic cells as marker
10.1016/0168-1656(92)90158-6
Entrapment of Intracytosolic Bacteria by Septin Cage-like Structures
10.1016/J.CHOM.2010.10.009
Priming by DNA Immunization Augments Protective Efficacy of Mycobacterium bovis Bacille Calmette-Guerin against Tuberculosis
10.1128/IAI.69.6.4174-4176.2001
Proteomic Analysis of the SH2 Domain-containing Leukocyte Protein of 76 kDa (SLP76) Interactome in Resting and Activated Primary Mast Cells
10.1074/MCP.A112.025908
Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria
10.1039/B803101K
Pathogenic and immunosuppressive properties of mycobacterial phenolic glycolipids
10.1016/J.BIOCHI.2017.03.012
ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria
10.1111/J.1462-5822.2012.01799.X
Sec61 blockade by mycolactone: A central mechanism in Buruli ulcer disease
10.1111/BOC.201800030
HOST IMMUNOMODULATION BY MYCOLACTONE, THE MYCOBACTERIUM ULCERANS TOXIN
10.1016/J.TOXICON.2017.12.018
Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges
10.1073/PNAS.1714765115
Parallel derivation of isogenic human primed and naive induced pluripotent stem cells
10.1038/S41467-017-02107-W
Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors
10.1038/S41590-018-0049-7
Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines
10.1186/S13073-018-0568-8
Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis
10.1093/EMBOJ/19.7.1525
